Starting summer off strong! This June Trevi is headed to the American Cough Conference, CPDD 87th Annual Scientific Meeting and BIO International Convention. Read more: ow.ly/2gHj50W0JWy #ChronicCough

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough. For more information: ow.ly/zmHI50W2cI9

We are pleased to share the positive topline results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough.   Join our conference call today, June 2nd, at 8:30 a.m. ET.  Read the press release: ow.ly/MCzh50W2spG $TRVI

Trevi is excited to participate in the 10th American Cough Conference. James Cassella, Trevi’s CDO, will be presenting on the baseline demographics and characteristics from the Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) in patients with refractory chronic cough (RCC).

Don’t miss our corporate presentation at the BIO International Convention next week! We can’t wait to discuss the exciting results from our Phase 2b CORAL Trial of Haduvio for the treatment of chronic cough in patients with Idiopathic Pulmonary Fibrosis (IPF). #ChronicCough

Trevi was proud to present on the Assessment of Human Abuse Potential of Nalbuphine in Non-Dependent Recreational Drug Users at the CPDD 87th Annual Scientific Meeting last week. Check out the full poster here: ow.ly/bNte50WcgVN #ClinicalTrials

Trevi looks forward to attending Leerink Partners Therapeutics Forum: I&I Metabolism conference next week. Read the full press release: ow.ly/Hono50WiZkw #ControllingCoughWhereItCounts

Trevi’s senior leadership is heading to Oppenheimer’s 2025 Biotech in the Berkshires and Stifel’s 2025 Biotech Summer Summit this August. Be sure to connect with our team if you are attending. Read more: ow.ly/l40350WwCfu

Save the date for Trevi’s Second Quarter Earnings Call!   Join us on August 7th at 4:30p.m. Eastern Time for a live update on our second quarter earnings.  ow.ly/Tc5O50WyhR2 $TRVI #EarningsQ2 #Earnings

Today’s the day! The Oppenheimer & Co. Inc. 2025 Biotech in the Berkshires kicks off today. Jennifer Good, Trevi’s President & CEO, is excited to connect with attendees during her presentation tomorrow, August 5, at 8:35 a.m. ET, where she will discuss “Why Now” for Trevi. #ChronicCough

Don't miss Trevi’s Second Quarter Earnings Call! Join us today, August 7th, at 4:30 p.m. ET for a live update on our earnings. Press Release: ow.ly/ueKJ50WBH08 $TRVI #EarningsQ2 #ChronicCough

Don’t miss Trevi’s senior leadership Stifel 2025 Biotech Summer Summit, starting today. Attending the Summit? Connect with our team to learn more about the positive study results released in the first half of 2025 for Haduvio, our investigational therapy for chronic cough.

Check out the highlights from Trevi’s Second Quarter Earnings Call. For a closer look at our Q2 earnings, click here to listen to the full recording of the call ow.ly/Pqxh50WCOfZ $TRVI #EarningsCallQ2

Trevi’s senior leadership is excited for an eventful month ahead! Our team looks forward to every opportunity to share our mission of bringing relief to patients living with chronic cough. Read more: ow.ly/X8bw50WNtjU #ChronicCough

Coming up this week! Connect with Trevi leadership at the 2025 Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference 2025. Let’s talk innovation, impact, and the future of chronic cough treatment. #UnmetNeed #ChronicCough Cantor Wells Fargo

Tune in to our in-person Fireside Chat Morgan Stanley on September 9 at 4:05 PM ET. Click here to watch the livestream: ow.ly/10Xk50WNK1B Trevi is proud to be part of the conversation at Morgan Stanley and H.C. Wainwright & Co.! #ControllingCoughWhereItCounts #HCWConference

Trevi looks forward to joining industry leaders at the 2025 Leerink Partners Biopharma Summit. Excited to connect? So are we! #ControllingCoughWhereItCounts

Trevi is proud to return to the European Respiratory Society Congress, where the global respiratory community advances care. Read the full press release here: ow.ly/VHpM50WYI9s #ChronicCough #RCC

Trevi is proud to be presenting at CHEST 2025! We are excited to share our clinical advancements of nalbuphine ER, our investigational treatment for chronic cough. Read the full PR here: ow.ly/HgQp50X8qYi #CHEST2025 #ChronicCough CHEST

Tune in today at 1pm ET to hear from our President and CEO, Jennifer Good, as she meets with LifeSci Advisors virtually to discuss our investigational therapy Haduvio (nalbuphine ER) and it's potential in chronic cough. #ChronicCough #Biotech